Neoadjuvant Chemotherapy in Invasive Bladder Cancer

por Oliver, R.T.D.
Publicado 1991

National Cancer Institute Monograph No. 49. Workshop on Geniturinary Cancer Immunology

por Oliver, R. T. D.
Publicado 1980

Bladder Tumors and Other Topics in Urological Oncology

por Oliver, R. J. D.
Publicado 1980

Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group

por Powles, T, Shamash, J, Berney, D, Oliver, R T D
Publicado 2003

DNA topoisomerase I and II expression in drug resistantgerm cell tumours

por Berney, D M, Shamash, J, Gaffney, J, Jordan, S, Oliver, R T D
Publicado 2002

Chlorambucil and lomustine (CL56) in absolute hormone refractory prostate cancer: re-induction of endocrine sensitivity an unexpected finding

por Shamash, J, Dancey, G, Barlow, C, Wilson, P, Ansell, W, Oliver, R T D
Publicado 2005

Evidence for a schedule-dependent deleterious interaction between paclitaxel, vinblastine and cisplatin (PVC) in the treatment of advanced transitional cell carcinoma

por Mulatero, C, McClaren, B R, Mason, M, Oliver, R T D, Gallagher, C J
Publicado 2000

IPM chemotherapy in cytokine refractory renal cell cancer

por Shamash, J, Steele, J P, Wilson, P, Nystrom, M, Ansell, W, Oliver, R T D
Publicado 2003

Risk factors for testicular germ cell tumours by histological tumour type

por Coupland, C A C, Chilvers, C E D, Davey, G, Pike, M C, Oliver, R T D, Forman, D
Publicado 1999

GAMEC – a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours

por Shamash, J, Powles, T, Ansell, W, Stebbing, J, Mutsvangwa, K, Wilson, P, Asterling, S, Liu, S, Wyatt, P, Joel, S P, Oliver, R T D
Publicado 2007

Pre-induction LDH as a prognostic factor for outcome of high dose chemotherapy (HDCT) for germ cell tumours relapsing or refractory to conventional chemotherapy

por Shamash, J, Oliver, R T D, Gallagher, C J, Newland, A C, Lister, T A, Kelsey, S, Gupta, R K, O'Doherty, C A
Publicado 2000

GAMEC – a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours

por Shamash, J, Powles, T, Ansell, W, Berney, D, Stebbing, J, Mutsvangwa, K, Wilson, P, Asterling, S, Liu, S, Wyatt, P, Joel, S P, Oliver, R T D
Publicado 2007

A Medical Research Council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma

por Horwich, A, Oliver, R T D, Wilkinson, P M, Mead, G M, Harland, S J, Cullen, M H, Roberts, J T, Fossa, S D, Dearnaley, D P, Lallemand, E, Stenning, S P
Publicado 2000

Feasibility of aspirin and/or vitamin D3 for men with prostate cancer on active surveillance with Prolaris® testing

por Dinneen, Eoin, Shaw, Gregory L., Kealy, Roseann, Alexandris, Panos, Finnegan, Kier, Chu, Kimberley, Haidar, Nadia, Santos‐Vidal, Sara, Kudahetti, Sakunthala, Moore, Caroline M., Grey, Alistair D. R., Berney, Daniel M., Sahdev, Anju, Cathcart, Paul J., Oliver, R. Timothy D., Rajan, Prabhakar, Cuzick, Jack, Cuzick, Jack, Madaan, Sanjeev, Pati, Jhumur, Chowdhury, Abdul M., Birch, Brian R. P., Dudderidge, Timothy J., Moore, Caroline M., Grey, Alistair D. R., Shaw, Gregory L., Jefferson, Kieran P., Kynaston, Howard G., Rajan, Prabhakar, Green, James S. A., Cathcart, Paul J., Berney, Daniel M., Powles, Thomas, Oliver, R. Timothy D., Sahdev, Anju, Kealy, Roseann, Kemp, Victoria, Alexandris, Panos, Finnegan, Kier, Chu, Kimberly
Publicado 2022